EBF vs KELYB

EBF exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a nearly debt-free balance sheet (Debt/Equity 0.01). While the current price of $20.33 sits below the Graham Number of $21.35, suggesting defensive value, this is offset by a significant recent decline in Q/Q EPS growth (-28.6%) and a bearish technical trend (0/100). The company functions as a high-stability value play with an attractive 4.92% dividend yield, but lacks the growth catalysts necessary for a bullish rating.

KELYB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, placing it firmly in the 'Weak' health category. While the stock appears undervalued on a Price-to-Book (0.55) and Price-to-Sales (0.13) basis, this is likely a value trap given the negative profit margins (-5.98%) and contracting revenue (-11.90%). The combination of a negative ROE (-22.98%) and significant insider selling suggests a deteriorating business model. Despite a recent 1-year price recovery, the long-term 5-year trend remains deeply negative (-43.5%).